Myriad Genetics stock. Shares trade on Nasdaq.

By Christina Vaughn, Background & Management desk. Reviewed on July 7, 2026 at 7:49 p.m. ET.

Myriad Genetics Inc (ISIN US62855J1043) trades on Nasdaq as a molecular diagnostics company, with its business centered on genetic testing and related clinical services. The stock gives US investors exposure to healthcare demand, reimbursement dynamics and the cadence of test adoption.

Business model first

Myriad sells laboratory-developed tests and other diagnostic services that are used in oncology, women's health and pharmacogenomics. That mix makes the company's revenue profile dependent on both physician utilization and payer coverage decisions.

Market context

The shares remain a US-listed healthcare name, which keeps the focus on operating execution and cash discipline rather than broad index effects. For investors, the important question is whether test volumes and pricing can support steadier results over time.

Product line

One core offering is hereditary cancer testing, which is designed to identify inherited risk markers and guide treatment or screening decisions. That product area sits at the center of Myriad's diagnostics franchise.

Stock snapshot

Myriad Genetics shares last traded on Nasdaq in the absence of a fresh live quote in the available search results.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.